Singapore-based medical technology firm Biolidics Limited plans to raise S$3.13 million ($2.2 million) from a share placement exercise to fuel its business expansion and pursue new opportunities, according to a company statement.
The cancer diagnostic solutions-focused company said it planned to issue 17,858,000 new ordinary shares at an issue price of S$0.175 per share, which represents a discount of approximately 7.3 per cent to its volume-weighted average of S$0.188 per share, for all trades done on Catalist on March 13.
